CMO SynCo enters Japanese market
CMO SynCo Bio Partners has entered the Japanese biologics production market, which it views as a growth opportunity, by signing its first contract with an emerging company based in the country.
The Netherlands-based contract manufacturing organisation (CMO) will work on the undisclosed company’s live biotherapeutic based anticancer drug. Under the terms of the contract SynCo will initially act as a consultant and assist the client with in-house process development of the therapeutic.
Once this is complete the developed process will be transferred to SynCo’s facility in Amsterdam, the Netherlands for scale up before good manufacturing practice (GMP) for Phase I trials.
